BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37296928)

  • 1.
    Overbeck TR; Reiffert A; Schmitz K; Rittmeyer A; Körber W; Hugo S; Schnalke J; Lukat L; Hugo T; Hinterthaner M; Reuter-Jessen K; Schildhaus HU
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
    Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence
    Fu Y; Li Z; Gao F; Yang J; Wu H; Zhang B; Pu X; Fan X
    Front Oncol; 2021; 11():669197. PubMed ID: 33996597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment.
    de Oliveira Cavagna R; de Andrade ES; Tadin Reis M; de Paula FE; Noriz Berardinelli G; Bonatelli M; Ramos Teixeira G; Garbe Zaniolo B; Mourão Dias J; da Silva FAF; Baston Silva CE; Xavier Reis M; Lopes Maia E; de Alencar TS; Jacinto AA; da Nóbrega Oliveira REN; Molina-Vila MA; Ferro Leal L; Reis RM
    Sci Rep; 2023 Dec; 13(1):21168. PubMed ID: 38036758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.
    Zito Marino F; Buono S; Montella M; Giannatiempo R; Messina F; Casaretta G; Arpino G; Vita G; Fiorentino F; Insabato L; Sgambato A; Orditura M; Franco R; Accardo M
    J Pathol Clin Res; 2023 Sep; 9(5):367-377. PubMed ID: 37143440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
    Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
    Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic characteristics and diagnostic methods of
    Feng J; Li Y; Wei B; Guo L; Li W; Xia Q; Zhao C; Zheng J; Zhao J; Sun R; Guo Y; Brcic L; Hakozaki T; Ying J; Ma J
    Transl Lung Cancer Res; 2022 Apr; 11(4):617-631. PubMed ID: 35529790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
    Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
    Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
    Hum Pathol; 2024 Apr; ():. PubMed ID: 38653403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An odd dancing couple. Non-small cell lung carcinoma with coexisting EGFR mutation and NTRK-1 translocation: A case report.
    Robledano R; Lozano MD
    Diagn Cytopathol; 2024 Apr; ():. PubMed ID: 38634549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
    Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
    Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
    J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world challenges in undertaking
    Poh A; Sammour A; Mathai J; Peverall J; Van Vliet C; Asadi K; Parakh S
    J Thorac Dis; 2023 Jul; 15(7):3811-3817. PubMed ID: 37559603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
    Pecciarini L; Brunetto E; Grassini G; De Pascali V; Ogliari FR; Talarico A; Marra G; Magliacane G; Redegalli M; Arrigoni G; Lazzari C; Gregorc V; Bulotta A; Doglioni C; Cangi MG
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.